表紙
市場調查報告書

數位療法和醫療的影響

Digital Therapeutics and Their Impact on Healthcare

出版商 GlobalData 商品編碼 874795
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
數位療法和醫療的影響 Digital Therapeutics and Their Impact on Healthcare
出版日期: 2019年06月10日內容資訊: 英文 130 Pages
簡介

本報告提供主要8個國家 (法國、德國、義大利、西班牙、英國、美國、日本、中國)的數位療法 (DTx) 調查分析,目前上市產品和開發中產品為焦點之系統性資訊。

第1章 序文

第2章 摘要整理

第3章 概要:數位療法 (DTx)

  • 數位療法定義
  • 數位醫學定義
  • 數位醫療的主要標準
  • 數位健康中DTx的地位

第4章 DTx 技術

  • 數位療法的使用
  • 數位療法的種類
  • 臨床試驗的DTx
  • KOL預測

第5章 DTx 上市產品

  • 主要的上市產品
  • 主要上市產品
  • 已上市DTx:設備的各類型
  • 已上市DTx:各適應症

第6章 DTx 開發中產品

  • 領先的開發中產品
  • 主要的開發中產品
  • 臨床試驗製圖
  • 開發平台DTx:設備的各類型
  • 開發平台DTx:各適應症

第7章 數位醫學

  • 概要
  • 已上市數位醫學
  • Proteus的Discover產品
  • 臨床試驗製圖
  • 開發平台數位醫學

第8章 DTx 醫療的影響

  • 概要
  • 臨床的未滿足需求中DTx與數位醫學所扮演的角色
  • KOL預測
  • 患者預測
  • 供應商預測
  • 保險者預測
  • 醫療制度
  • 醫生的想法

第9章 數位療法趨勢

  • 概要
  • 臨床試驗設計
  • 法規核准
  • 製藥公駕駛者會
  • 交易形勢
  • KOL預測
  • 案例研究

第10章 市場機會

  • 概要
  • 推動市場要素
  • 市場障礙
  • 醫生的想法

第11章 DTx 市場進入

  • 美國、EU的法規、核准
  • 日本、中國的法規、核准
  • 對DTx的打入市場策略的制定
  • 保險者的想法
  • 美國的DTx法規
  • 美國的DTx償付
  • 英國的DTx法規
  • 英國的保險者的想法

第12章 市場預測

  • 建議
  • DTX的未來方向性

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCHT025

Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory-approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions.

This report provides an overview of current marketed and pipeline DTx products within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China).

Scope

  • This report combines primary research from a cross-specialty panel of experts with in-house analyst expertise to provide an assessment of the development landscape.
  • Components of the slide deck include primary and secondary research:
  • Quotes from 10 key opinion leaders (7 US, 1 EU, 2 Japan) and 2 payers (1 US and 1 UK)
  • Summary of DTx product definitions and classifications
  • Overview of key DTx marketed products and key pipeline DTx products
  • Trends in DTx market
  • Call-outs of key information and details
  • Insight from GlobalData's specialist healthcare analysts.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global DTx market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DTx market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface

  • 1.1 Abbreviations
  • 1.2 Related Reports
  • 1.3 Upcoming Related Reports

2. Executive Summary

  • 2.1 Key Findings
  • 2.2 KOL and Payer Insights

3. Overview - Digital Therapeutics (DTx)

  • 3.1 Digital Therapeutics Definition
  • 3.2 Digital Medicine Definition
  • 3.3 Key Criteria of Digital Therapeutics
  • 3.4 Positioning DTx Within Digital Health

4. DTx Technologies

  • 4.1 Use of Digital Therapeutics
  • 4.2 Types of Digital Therapeutics
  • 4.3 DTx in Clinical Trials
  • 4.4 KOL Perspectives

5. DTx Marketed Products

  • 5.1 Leading Marketed Products
  • 5.2 Key Marketed Products
  • 5.3 Marketed DTx by Device Type
  • 5.4 Marketed DTx by Indication

6. DTx Pipeline Products

  • 6.1 Leading Pipeline Products
  • 6.2 Key Pipeline Products
  • 6.3 Clinical Trial Mapping
  • 6.4 Pipeline DTx by Device Type
  • 6.5 Pipeline DTx by Indication

7. Digital Medicine

  • 7.1 Overview
  • 7.2 Marketed Digital Medicine
  • 7.3 Proteus Discover Products
  • 7.4 Clinical Trial Mapping
  • 7.5 Pipeline Digital Medicine

8. DTx Impact on Healthcare

  • 8.1 Overview
  • 8.2 Role of DTx and Digital Medicine in Clinical Unmet Needs
  • 8.3 KOL Perspectives
  • 8.4 Patient Perspective
  • 8.5 Provider Perspective
  • 8.6 Payer Perspective
  • 8.7 Health System
  • 8.8 What Do Physicians Think?

9. Trends in Digital Therapeutics

  • 9.1 Overview
  • 9.2 Clinical Trial Design
  • 9.3 Regulatory Approvals
  • 9.4 Opportunities for Pharma Companies
  • 9.5 Deals Landscape
  • 9.6 KOLs Perspectives
  • 9.7 Case Studies

10. Market Opportunities

  • 10.1 Overview
  • 10.2 Market Drivers
  • 10.3 Market Barriers
  • 10.4 What Do Physicians Think?

11. DTx Market Access

  • 11.1 Regulatory and Approval in US and EU
  • 11.2 Regulatory and Approval in Japan and China
  • 11.3 Developing a Market Access Strategy for DTx
  • 11.4 What Do Payers Think?
  • 11.5 DTx Regulation in US
  • 11.6 DTx Reimbursement in US
    • 11.6.1 What Do US Payers Think?
  • 11.7 DTx Regulation in UK
  • 11.8 DTx Reimbursement in UK
    • 11.8.1 What Do UK Payers Think?

12. Market Outlook

  • 12.1 Recommendations
  • 12.2 Future Directions for DTx

13. Appendix

  • 13.1 Sources
  • 13.3 Methodology
  • 13.4 Primary Research
  • 13.5 About the Authors
  • 13.6 About GlobalData
  • 13.7 Contact Us